Vitamin D receptor, STAT3, and TET2 cooperate to establish tolerogenesis

The active form of vitamin D, 1,25-dihydroxyvitamin D3, induces a stable tolerogenic phenotype in dendritic cells (DCs). This process involves the vitamin D receptor (VDR), which translocates to the nucleus, binds its cognate genomic sites, and promotes epigenetic and transcriptional remodeling. In...

Descripción completa

Detalles Bibliográficos
Autores: Català-Moll, Francesc|||0000-0002-2354-8648, Ferreté-Bonastre, Anna G|||0000-0003-3327-6129, Godoy-Tena, Gerard|||0000-0003-3832-5794, Morante-Palacios, Octavio|||0000-0002-6435-2756, Ciudad, Laura|||0000-0002-5219-6792, Barberà, Laura|||0000-0002-0883-657X, Fondelli, Federico|||0000-0002-6875-4744, Martínez Cáceres, Eva María|||0000-0002-6762-8025, Rodríguez-Ubreva, Javier|||0000-0003-4707-4536, Li, Tianlu|||0000-0001-7152-4870, Ballestar, Esteban|||0000-0002-1400-2440
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:270600
Acceso en línea:https://ddd.uab.cat/record/270600
https://dx.doi.org/urn:doi:10.1016/j.celrep.2021.110244
Access Level:acceso abierto
Palabra clave:Tolerogenesis
Dendritic cells
Vitamin D
VDR
STAT3
TET2
IL-6-JAK-STAT
DNA methylation
JAK2
Descripción
Sumario:The active form of vitamin D, 1,25-dihydroxyvitamin D3, induces a stable tolerogenic phenotype in dendritic cells (DCs). This process involves the vitamin D receptor (VDR), which translocates to the nucleus, binds its cognate genomic sites, and promotes epigenetic and transcriptional remodeling. In this study, we report the occurrence of vitamin D-specific DNA demethylation and transcriptional activation at VDR binding sites associated with the acquisition of tolerogenesis in vitro. Differentiation to tolerogenic DCs associates with activation of the IL-6-JAK-STAT3 pathway. We show that JAK2-mediated STAT3 phosphorylation is specific to vitamin D stimulation. VDR and the phosphorylated form of STAT3 interact with each other to form a complex with methylcytosine dioxygenase TET2. Most importantly, pharmacological inhibition of JAK2 reverts vitamin D-induced tolerogenic properties of DCs. This interplay among VDR, STAT3, and TET2 opens up possibilities for modulating DC immunogenic properties in clinics.